New microRNA Data Could Classify Bladder Cancer by Type

Oct 22, 2009

(PhysOrg.com) -- Data published in Cancer Research, a journal of the American Association for Cancer Research, offers new insights into the biology of urothelial carcinoma of the bladder. Specifically, microRNA profiles differ according to clinical disease phenotype, therefore, scientists may be able to use these profiles to identify gene-regulatory and biological differences between tumors.

“We identified new mechanisms of urothelial carcinogenesis. Consequently, microRNA could be used as disease biomarkers and therapeutic targets,” said lead researcher Freddie C. Hamdy, M.D., professor of surgery and professor of urology and head of the Nuffield Department of Surgery at the University of Oxford, United Kingdom.

Hamdy, along with Jim Catto, M.D., Ph.D., a GlaxoSmithKline clinician-scientist and senior lecturer in urology at the University of Sheffield, United Kingdom, and their research team evaluated microRNA expression levels in urothelial of the bladder. The aim was to better understand the disease biology. Using real-time , these researchers examined the expression of 322 microRNAs and their processing machinery in 78 normal and malignant urothelial samples, according to the study.

Results showed differences in microRNA expression between low- and high-grade urothelial carcinoma. Compared to disease-free controls, 11 percent of microRNAs in patients with urothelial carcinoma of the bladder had altered expression levels. Phenotype-specific microRNA changes facilitated gene-regulatory events typical for these tumors, indicating their importance in disease pathogenesis, Hamdy said.

The research team also found that DNA methyltransferase inhibition was associated with significant upregulation of six miRs in low-grade urothelial cell carcinoma.

“We expected differences to occur between these distinct tumor phenotypes, as they are known to share very few molecular mechanisms,” he said. “However, we did not expect FGFR3 upregulation by microRNA to occur prior to the onset of mutation. This finding suggests novel epigenetic-genetic interactions.”

Stephen J. Meltzer, M.D., an editorial board member for Research, believes this study - one of the first to evaluate altered microRNA expression levels in this form of cancer - is novel and well-designed.

“It is possible that in the future, these altered microRNAs could be investigated as potential biomarkers for the early detection of primary or metachronous cancer,” he said.

Additional studies are now indicated to evaluate levels of these microRNAs at discrete stages of urothelial carcinogenesis, according to Meltzer, who is the Harry and Betty Myerberg/Thomas R. Hendrix Professor of Gastroenterology in the Departments of Medicine and Oncology at The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center.

Provided by American Association for Cancer Research (news : web)

Explore further: Bone loss drugs may help prevent endometrial cancer

add to favorites email to friend print save as pdf

Related Stories

Scientists move closer to bio-engineered bladders

Aug 01, 2007

Researchers at the University of York are using an understanding of the special cells that line the bladder to develop ways of restoring continence to patients with serious bladder conditions, including cancer.

Bladder cells feel stretch

Aug 07, 2009

Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS), and Prof. Masayuki Takeda, Dr. Isao Araki and Dr. Tsutomu Mochizuki (Yamanashi Univ.), found ...

Molecules may help predict survival in liver cancer

Jan 30, 2008

Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others, new research suggests.

MicroRNA convicted of triggering metastasis

Sep 26, 2007

The jury is in: microRNAs can cause tumors to metastasize. These tiny molecules fine-tune protein production and play a powerful role in biological processes ranging from development to aging. Now scientists have proved that ...

Recommended for you

Bone loss drugs may help prevent endometrial cancer

8 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.